Testing a new drug for advanced cancers with gene changes
Part of Brain & nervous system, Cancer clinical trials.
This study tests a new oral drug, DSB2455, for people with advanced breast, prostate, ovarian, or pancreatic cancers that have certain gene changes. It aims to see if the drug is safe and whether it helps shrink or control the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older.
- You have advanced breast, prostate, ovarian, or pancreatic cancer with a specific gene change.
- You have had at least one prior cancer treatment.
- You are able to take care of yourself (daily activities aren't limited).
- You haven't taken a PARP1-selective inhibitor before.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called DS-2243a for people with advanced solid tumors that have stopped responding to standard treatments. It targets a specific protein found in some cancers, and you need to have a particular immune system marker for it to work.
This trial tests a new pill called DAT-2645 for people with advanced solid tumors that have a specific DNA repair problem (like a BRCA gene change). It aims to see if the drug is safe and effective when standard treatments have stopped working.
This study tests an experimental drug called VVD-159642 in people with advanced solid tumors that have specific genetic changes (RAS or EGFR alterations, or HER2 overexpression). The goal is to see if the drug is safe and tolerable.
This trial is testing a new drug called DM5167 for people whose advanced solid tumors have a BRCA1 or BRCA2 gene mutation. The goal is to see if the drug can shrink tumors or slow their growth.
This trial tests a new oral drug, DAT-1604, for people with advanced solid tumors who have run out of standard options. The goal is to see if it is safe, how the body processes it, and whether it can shrink tumors.
This study tests a new drug called DAT-2645 for ovarian cancer patients with specific genetic changes (BRCA mutations or HRD-positive status) who haven't responded well to standard treatments. The drug may help slow or stop cancer growth in patients whose tumors have DNA-repair problems.
Hear when a new Advanced Cancers (Breast, Ovarian, mCRPC, Pancreatic Ductal Adenocarcinoma (PDAC), Brain Mets) With Specific Mutations (Homologous Recombination Deficiency) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.